Search Results - "Christians, U."

Refine Results
  1. 1

    Development and validation of an LC-MS/MS assay for the quantification of allopregnanolone and its progesterone-derived isomers, precursors, and cortisol/cortisone in pregnancy by Mayne, G., De Bloois, E., Dabelea, D., Christians, U.

    Published in Analytical and bioanalytical chemistry (01-09-2021)
    “…Neuroactive steroids are potent neuromodulators that play a critical role in both maternal and fetal health during pregnancy. These stress-responsive compounds…”
    Get full text
    Journal Article
  2. 2

    Development of a Physiologically‐Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content by Emoto, C, Fukuda, T, Cox, S, Christians, U, Vinks, AA

    “…Sirolimus is an inhibitor of mammalian target of rapamycin (mTOR) and is increasingly being used in transplantation and cancer therapies. Sirolimus has low…”
    Get full text
    Journal Article
  3. 3

    Mechanisms of clinically relevant drug interactions associated with tacrolimus by Christians, Uwe, Jacobsen, Wolfgang, Benet, Leslie Z, Lampen, Alfonso

    Published in Clinical pharmacokinetics (2002)
    “…The clinical management of tacrolimus, a macrolide used as immunosuppressant after transplantation, is complicated by its narrow therapeutic index in…”
    Get full text
    Journal Article
  4. 4

    Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study by Klawitter, J, Anderson, N, Klawitter, J, Christians, U, Leibfritz, D, Eckhardt, S G, Serkova, N J

    Published in British journal of cancer (24-03-2009)
    “…The goal of this study was to evaluate the time course of metabolic changes in leukaemia cells treated with the Bcr-Abl tyrosine kinase inhibitor imatinib…”
    Get full text
    Journal Article
  5. 5

    SLCO1B1 Genotype Influences the Drug-Drug Interaction between Cyclosporine and Pravastatin by Aquilante, C.L, Page, R.L, Brieke, A, Hopley, C.W, Christians, U, Hoffman, K.L, Schniedewind, B

    “…Purpose Cyclosporine (CYA) increases pravastatin (PRAV) plasma exposure by inhibiting the OATP1B1 ( SLCO1B1 ) transporter. The aim of this study was to…”
    Get full text
    Journal Article
  6. 6
  7. 7
  8. 8

    Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability by Lampen, A, Christians, U, Guengerich, F P, Watkins, P B, Kolars, J C, Bader, A, Gonschior, A K, Dralle, H, Hackbarth, I, Sewing, K F

    Published in Drug metabolism and disposition (01-12-1995)
    “…The small intestinal metabolism of tacrolimus, which is used as an immunosuppressant in transplantation medicine, was investigated in this study. Tacrolimus…”
    Get more information
    Journal Article
  9. 9

    Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat by Sattler, M, Guengerich, F P, Yun, C H, Christians, U, Sewing, K F

    Published in Drug metabolism and disposition (01-09-1992)
    “…The hepatic cytochrome P-450 responsible for metabolism of the structurally related macrolides FK506 and rapamycin in humans was identified using in vitro…”
    Get more information
    Journal Article
  10. 10

    Cyclosporin metabolism in transplant patients by Christians, U, Sewing, K F

    “…The immunosuppressant cyclosporin, a cyclic undecapeptide, is metabolized to more than 30 metabolites. Cytochrome P450IIIA enzymes located in liver and small…”
    Get more information
    Journal Article
  11. 11

    In Vitro Evaluation of the Disposition of A Novel Cysteine Protease Inhibitor by JACOBSEN, Wolfgang, CHRISTIANS, Uwe, BENET, Leslie Z

    Published in Drug metabolism and disposition (01-11-2000)
    “…K11777 ( N -methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl) is a potent, irreversible cysteine protease inhibitor. Its therapeutic targets are cruzain, a…”
    Get full text
    Journal Article
  12. 12

    Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients by TROTTER, J. F., OSBORNE, J. C., HELLER, M., CHRISTIANS, U.

    Published in Alimentary pharmacology & therapeutics (01-07-2005)
    “…Summary Background : In our cohort of patients with hepatitis‐C virus, which is the most common indication for liver transplantation, we have noted higher…”
    Get full text
    Journal Article
  13. 13

    Biochemical Mechanisms of Cyclosporine Neurotoxicity by Serkova, Natalie J, Christians, Uwe, Benet, Leslie Z

    Published in Molecular interventions (01-04-2004)
    “…Proper management of chemotoxicity in transplant patients requires detailed knowledge of the biochemical mechanisms underlying immunosuppressant toxicity…”
    Get full text
    Journal Article
  14. 14

    Metabolism of Sirolimus and Its Derivative Everolimus by Cytochrome P450 3A4:  Insights from Docking, Molecular Dynamics, and Quantum Chemical Calculations by Kuhn, Bernd, Jacobsen, Wolfgang, Christians, Uwe, Benet, Leslie Z, Kollman, Peter A

    Published in Journal of medicinal chemistry (07-06-2001)
    “…A combination of quantum chemical calculations and molecular simulations (DOCKing and molecular dynamics) is used to investigate the metabolism of sirolimus…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Worsening of long-term myocardial function after successful pharmacological pretreatment with cyclosporine by Laudi, S, Weimann, J, Haschke, M, Trump, S, Schmitz, V, Christians, U, Kaisers, U, Steudel, W

    “…Pretreatment with cyclosporine (CsA) decreases infarct size 24h after myocardial ischemia/reperfusion (I/R). The goal of this study was to determine effects of…”
    Get full text
    Journal Article
  17. 17

    Biotransformation of cyclosporin in primary rat, porcine and human liver cell co-cultures by Schmelzer, E., Acikgoez, A., Frühauf, N. R., Crome, O., Klempnauer, J., Christians, U., Bader, A.

    Published in Xenobiotica (01-08-2006)
    “…The purpose of this study was to investigate the species-specific cyclosporin biotransformation in primary rat, human, and porcine liver cell cultures, and to…”
    Get full text
    Journal Article
  18. 18

    Combined immunosuppression with cyclosporine (NEORAL) and SDZ RAD in non-human primate lung transplantation : Systematic pharmacokinetic-based trials to improve efficacy and tolerability by HAUSEN, B, IKONEN, T, MORRIS, R. E, BRIFFA, N, BERRY, G. J, CHRISTIANS, U, ROBBINS, R. C, HOOK, L, SERKOVA, N, BENET, L. Z, SCHULER, W

    Published in Transplantation (15-01-2000)
    “…We studied the efficacy and tolerability of combined immunosuppressive therapy with cyclosporine A microemulsion (Neoral) plus the macrolide SDZ RAD 40-0…”
    Get full text
    Journal Article
  19. 19

    Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray- mass spectrometry by Streit, F, Christians, U, Schiebel, HM, Napoli, KL, Ernst, L, Linck, A, Kahan, BD, Sewing, KF

    Published in Clinical chemistry (Baltimore, Md.) (01-09-1996)
    “…Sirolimus (rapamycin) has a macrolide structure and is under clinical investigation as an immunosuppressant after organ transplantation. An HPLC/mass…”
    Get full text
    Journal Article Conference Proceeding
  20. 20

    79 IMMUNOASSAY CROSS-REACTIVITY TESTING OF THE MAJOR EVEROLIMUS METABOLITES IN THE BLOOD OF KIDNEY TRANSPLANT PATIENTS by Strom, T., Christians, U., Chan, L.

    Published in Journal of investigative medicine (01-01-2005)
    “…Everolimus was developed for use with cyclosporine as a new immunosuppressant in the prevention of rejection in transplant patients. It binds to FK binding…”
    Get full text
    Journal Article